FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114856098> ?p ?o ?g. }

• W2114856098 endingPage "86" @default.
• W2114856098 startingPage "85" @default.
• W2114856098 abstract "Prostate cancer is the most commonly diagnosed cancer in men and is the second most common cause of cancer-related deaths in the western world. Presently, the most common options for treatment are prostatectomy, radiation and chemotherapy. While certain immunotherapeutics have shown promise in clinical trials, the search for more effective, long-term treatment of later stages continues (1). Ganoderma lucidum is a species of the Basidiomycetes that is widely used in Traditional Chinese Medicine for prevention and treatment of a variety of human ailments including hypertension, bronchitis, arthritis, neurasthenia, hepatopathy, chronic hepatitis, nephritis, gastric ulcer, tumorigenic diseases, hypercholesterolemia, immunological disorders and scleroderma (2). Antitumor and immune enhancing properties of G. lucidum with no cytotoxicity makes it a good candidate to be effective in preventive oxidative damage and resulting disease (3).Ganoderic acids (GAs) are a class of closely related triterpenoids (derivatives from lanosterol) found in Ganoderma mushrooms. There have been efforts to identify the chemical constituents that may be responsible for the putative pharmacological effects. There are dozens of ganoderic acids that have been isolated and characterized, of which ganoderic acid A and ganoderic acid B are the best characterized. Some ganoderic acids have been found to possess biological activities including hepatoprotection, anti-tumor effects and 5-alpha reductase inhibition (4).One type of Ganoderic Acid (GD-DM), induces toxicity in both androgen dependent and independent prostate cancer. Prostate cancer cell lines (PC-3 (PC cell lines have high potential for metastasis) and LnCaP) were shown to be inhibited by GA-DM treatment in a dose dependent manner (5). Although there is no documented data involving the use of GA-DM in primary prostate tumor cells, the effectiveness of the drug in these cell lines suggests that GA-DM might work in attenuating the growth of primary tumors (5). LnCaP cells have been shown to retain androgen dependence and maintain the presence of androgen receptor (AR), thus resembling early-stage prostate cancer. PC-3 cells are androgen-independent and express little to no prostate specific antigen (PSA), two common features of metastatic, later-stage prostate cancer (5).It has also been shown that GA-DM treatment inhibits both the activity of 5- α-reductase and the conversion of testosterone to dihydrotestosterone (DHT). The inhibition of DHT activity possibly occurs due to the conformational similarity in the four-ringed steroidal structures of DHT and GA-DM. GA-DM competitively blocks the AR, preventing DHT binding and obstructing the normal DHT-mediated signaling pathway (5). While the effect of GA-DM on both 5-α-reductase and the AR mirrors that of other steroidal inhibitors, an even more promising effect of GA-DM is its inhibition of osteoclastogenesis. Osteoclastogenesis is a significant factor in prostate cancer metastasis, and GA-DM has been shown to limit this process in a pre-osteoclastic cell line (5). Several studies indicate that GA-DM treatment increases bone density and decreases osteoclastogenesis, suggesting that GA-DM could be a potential therapeutic alternative in prostate cancer. GA-DM can act through down-regulation of C-Fos (a protein encoded by the FOS gene) and NFATc1 (nuclear factor of activated T-cells, cytoplasmic 1 is a protein that in humans is encoded by the NFATC1 gene), which also regulate osteoclastogenesis as a result of stimulation through RANKL (receptor activator of nuclear factor kappa- B ligand) (6)." @default.
• W2114856098 created "2016-06-24" @default.
• W2114856098 creator A5017891553 @default.
• W2114856098 date "2012-08-25" @default.
• W2114856098 modified "2023-09-26" @default.
• W2114856098 title "Ganoderic Acid in the Treatment of Prostate Cancer" @default.
• W2114856098 cites W2020875816 @default.
• W2114856098 cites W2024840217 @default.
• W2114856098 cites W2032297247 @default.
• W2114856098 cites W2125386112 @default.
• W2114856098 cites W2172299463 @default.
• W2114856098 doi "https://doi.org/10.17795/jjnpp-7171" @default.
• W2114856098 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3941845" @default.
• W2114856098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24624160" @default.
• W2114856098 hasPublicationYear "2012" @default.
• W2114856098 type Work @default.
• W2114856098 sameAs 2114856098 @default.
• W2114856098 citedByCount "1" @default.
• W2114856098 countsByYear W21148560982015 @default.
• W2114856098 crossrefType "journal-article" @default.
• W2114856098 hasAuthorship W2114856098A5017891553 @default.
• W2114856098 hasBestOaLocation W21148560981 @default.
• W2114856098 hasConcept C121608353 @default.
• W2114856098 hasConcept C126322002 @default.
• W2114856098 hasConcept C143998085 @default.
• W2114856098 hasConcept C2776235491 @default.
• W2114856098 hasConcept C2780192828 @default.
• W2114856098 hasConcept C556039675 @default.
• W2114856098 hasConcept C71924100 @default.
• W2114856098 hasConceptScore W2114856098C121608353 @default.
• W2114856098 hasConceptScore W2114856098C126322002 @default.
• W2114856098 hasConceptScore W2114856098C143998085 @default.
• W2114856098 hasConceptScore W2114856098C2776235491 @default.
• W2114856098 hasConceptScore W2114856098C2780192828 @default.
• W2114856098 hasConceptScore W2114856098C556039675 @default.
• W2114856098 hasConceptScore W2114856098C71924100 @default.
• W2114856098 hasIssue "3" @default.
• W2114856098 hasLocation W21148560981 @default.
• W2114856098 hasLocation W21148560982 @default.
• W2114856098 hasLocation W21148560983 @default.
• W2114856098 hasOpenAccess W2114856098 @default.
• W2114856098 hasPrimaryLocation W21148560981 @default.
• W2114856098 hasRelatedWork W131936546 @default.
• W2114856098 hasRelatedWork W1497253641 @default.
• W2114856098 hasRelatedWork W1980245127 @default.
• W2114856098 hasRelatedWork W2060381175 @default.
• W2114856098 hasRelatedWork W2075763133 @default.
• W2114856098 hasRelatedWork W2088520467 @default.
• W2114856098 hasRelatedWork W2376423713 @default.
• W2114856098 hasRelatedWork W2386364393 @default.
• W2114856098 hasRelatedWork W3015759778 @default.
• W2114856098 hasRelatedWork W3032731309 @default.
• W2114856098 hasVolume "7" @default.
• W2114856098 isParatext "false" @default.
• W2114856098 isRetracted "false" @default.
• W2114856098 magId "2114856098" @default.
• W2114856098 workType "article" @default.